01/27/2026
A Heartbreaking Face of the Stimulant Crisis:
The Cardiac Toll of Stimulant Use
By Nicolas Garel, MD, MSc, FRCPC, and Paola Lavin, MD, MSc
Stimulants and m**hamphetamine-related emergencies are no longer confined to the pages of public health reports, they are unfolding daily in hospitals and emergency departments across North America. Clinicians increasingly encounter young adults experiencing chest pain, arrhythmias, or new cases of heart failure with no prior cardiac history but with a positive toxicology screen for (m**h)amphetamine. This clinical pattern, once rare, has become alarmingly common.
A new national cohort analysis by Garel and colleagues quantifies what frontline physicians have long observed. Using high-dimensional propensity score matching on more than 137,000 patients with substance use disorders (SUD), the authors compared the cardiovascular impact of stimulant use disorder (StUD) with non-stimulant SUD. Their findings showed that individuals with StUD had a 37% higher risk of major adverse cardiac events (MACE), including myocardial infarction, stroke, heart failure, or death, as compared with patients with non-stimulant SUDs. Even after rigorous adjustment for demographic and clinical confounders, mortality remained 23% higher. These results demonstrate that stimulant use carries distinct and substantial cardiovascular risk, even within an already vulnerable population.
Send a message to learn more